

### Background

Nexstim plc, headquartered in Helsinki, Finland and listed on both Nasdaq First North Finland and Nasdaq First North Sweden, is a medical technology company with a pioneering navigated brain stimulation system. The Company has pioneered the technology for brain diagnostics with its Navigated Brain Stimulation (NBS System), and based on the same technology platform Nexstim has developed a device for stroke therapy called Navigated Brain Therapy (NBT® System).

Navigated Brain Stimulation (NBS) by Nexstim, is the only CE-marked and FDA-cleared non-invasive solution to pre-surgical mapping of the motor cortex.


With its NBT® System, Nexstim is initially focusing on the rehabilitation of hand and arm movement (upper limb motor disability) which is the most common symptom following a stroke. Other major CE-marked therapeutic applications include chronic pain and depression.



Nexstim's Navigated Brain Stimulation® system

### About Navigated Brain Stimulation NBS®

Nexstim NBS System combines non-invasive Transcranial Magnetic Stimulation (TMS) with unique proprietary electric field modelling-based navigational capabilities, i.e. Navigational Transcranial Magnetic Stimulation (nTMS). A magnetic field induces an electric field in the brain leading to neuronal activation. Navigation is a key differentiator and competitive advantage in terms of its accuracy, repeatability and precise dosing capabilities.



#### How it works:

##### A solid solution platform

- The NBS System combines Magnetic Resonance Imaging (MRI-based imaging) guidance with non-invasive TMS and Electromyography (EMG) measurement for response measurement
- System integration, proprietary e-field algorithms and 3D visualisation provide unrivalled accuracy of targeting stimulation

#### FOCUS

Development of world leading image-guided transcranial magnetic stimulation (TMS) through Navigated Brain Therapy (NBT®) and Navigated Brain Stimulation (NBS), aiming to drastically improve the quality of life of patients.

#### MANAGEMENT

**Martin Jamieson**  
Chief Executive Officer

**Mikko Karvinen**  
Chief Financial Officer

**FOUNDED**  
25 October 2000

#### ADDRESS

Nexstim Plc  
Elimäenkatu 9 B  
FI-00510 Helsinki  
Finland  
Tel. +358 9 2727 1710  
[www.nexstim.com](http://www.nexstim.com)

#### INVESTOR AND MEDIA RELATIONS

Consilium Strategic Communications  
Mary-Jane Elliott, Ivar Milligan, Laura Thornton  
Tel: +44 20 3709 5700  
Email: [nexstim@consilium-comms.com](mailto:nexstim@consilium-comms.com)

## Status of Regulatory Development for Stroke





### US Regulatory Approval – THE NEXT STEP IN COMMERCIALISATION

In 2014, Nexstim initiated a pivotal Phase III clinical trial in 12 of the leading US rehabilitation centres (see above) on the therapeutic effects of Nexstim's NBT<sup>®</sup> following highly encouraging Phase II results.

Nexstim 510(k) De Novo documentation to the FDA based on the clinical data in June 2016. The submission included full data from a total of 173 patient from the Phase III multi-centre clinical trial (see Actual results on the rights). Positive data from the control group explained by active sham coil.

Feedback meeting with FDA was held in September 2016. Nexstim agreed that a limited size trial using a sham comparator of a different design will be designed and approved during H1 2017 according to the guidance received from FDA.




## About Navigated Brain Therapy NBT<sup>®</sup>

The Navigated Brain Therapy (NBT<sup>®</sup>) System is a device that uses navigated transcranial magnetic stimulation (nTMS) for multiple uses, including stroke rehabilitation, depression and chronic pain. Navigation is achieved by visualising the electric field (e-field) generated by the TMS coil in a 3D image rendered from the patient's MRI scan. Stimulation intensity is calculated from the accurate measurement of brain excitability and the personal resting motor threshold (MT) of each patient. The proven accuracy confirms optimal treatment location for the individual patient, and ensures that stimulation treatment is always repeated at the same location, every time and for every session.



In stroke therapy, using a patient's own MRI scan as a guide, Nexstim provides precisely targeted, personalised, magnetic stimulation to temporarily inhibit the healthy side of the brain, normalising the balance between the hemispheres. Because the injured side is no longer dominated by the healthy side of the brain, it is more responsive to the physiotherapy. This results in limb movement being potentially restored more quickly to better functionality.



## Market Potential

**4.5m**

New strokes each year in the US, Europe and China

Target patients with upper limb paralysis from population of stroke survivors

Focus on the period over 3 months post stroke